First-in-human phase 1 single ascending dose trial in healthy volunteers: subcutaneous RBD4059, an siRNA targeting factor XI (50–600 mg vs placebo), was well tolerated with no apparent safety concerns and gave dose-dependent, durable FXI suppression of over 90%.
RCT
Gabrielsen et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran)